fashion -WSS

fashion

author：focus 2025-09-27 12:57:00 - browse：6173

Several amyloid plaques forming between neurons in a brain — Amyloid plaques forming between neurons. Adobe

The Food and Drug Administration on Thursday granted full approval to the first therapy for Alzheimer’s disease clearly shown to slow the cognitive decline associated with the disease — a milestone in treatment, even if the benefits are modest.

The drug, called Leqembi, was developed by Eisai, the Japanese pharmaceutical company, and sold in partnership with Biogen. It previously secured conditional approval in January. The FDA’s decision will broaden patient access to the drug under the Medicare program and is likely to boost sales, even as Leqembi’s benefits and safety risks continue to be a source of debate.

Leqembi’s full, or traditional, approval was supported by results of a large clinical trial in which the drug slowed the rate of cognitive and functional decline by 27% compared to a placebo. Leqembi also beat placebo on a series of secondary measures of Alzheimer’s, and it had a dramatic effect on clearing toxic brain plaques called beta-amyloid, which play a role in the progression of the disease.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How to save PrEP access — and even expand it
Next article： TikTok, Instagram influencers need more rules for drug ads

hotspot

WSS

FDA endorses new sterilization method for medical devices

To bolster infectious disease surveillance, genomics powerhouses team up

The biotech scorecard for Q1: 17 stock

Inaction leaves children at risk from dangerous chemotherapy drug

Federal weight loss drug coverage is 30 years out of date

Flu vaccine reformulation won't be easy, manufacturers warn

Wikipedia

fashion

Wikipedia

Medicare proposal to cover medical devices draws a mixed reaction

Printout prescription drug information shouldn’t go digital

Jerome Adams on the need for new antivirals for Covid

There's an unseen cost to disruptive road

Medical records are filled with copy

AdventHealth escalates lawsuit against insurance vendor Multiplan

Malaria cases in Florida and Texas: Here’s what you need to know

Immunocompromised patients offer clues on chronic Covid

Cancer drug shortages should be causing more outrage

Susan Tousi leaves Illumina to head cancer liquid biopsy startup

focus

Inaction leaves children at risk from dangerous chemotherapy drug

Antibiotic resistance and the global rise in human conflict

CVS is on a mission to consolidate health care. Will it work?

Ahead of JPM, here's who's profiting most in health care

JPM: CVS says Medicare Advantage patients are impacting profits

Ahead of JPM, here's who's profiting most in health care

leisure time

hotspot

focus

hotspot